Review
BibTex RIS Cite

The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies

Year 2023, Volume: 27 Issue: 2, 22 - 33, 27.06.2025

Nadir Gül

Abstract

Endothelin and its two different cognate receptors have been implicated in a wide variety of
pathophysiological conditions since it was first identified as a vasoactive local hormone.
Especially in the last decade, the studies revealed that the aberrant expression of endothelin axis has critical importance
in the cancer biology involving in neovascularization, cellular survival, metastasis as well as drug resistance, by taking
part in different signalling mechanisms within the cell.
This situation has attracted the attention of many scientists to investigate not only reveal the molecular mechanistic role
of endothelin axis in cancer pathophysiology but also design new drugs targeting the endothelin axis. Further studies
suggest that utilizing endothelin axis as a new diagnostic parameter to define malignant features and monitor the
prognoses of cancer
This study, which was compiled from both preclinical and clinical studies, was prepared to provide an overview of
the potential role of the endothelin axis in cancer biology, as well as an overview of the drugs developed against the
endothelin axis

Keywords

Endothelin 1 Endothelin Receptor A Endothelin Receptor B Endothlin Antagonists Cancer

References

  • Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003;88[2]:163-166. [CrossRef]
  • Rosanò L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci [Lond]. 2002;103 Suppl 48:306S-309S. [CrossRef]
  • Eberle J, Fecker LF, Orfanos CE, Geilen CC. Endothelin-1 decreases basic apoptotic rates in human melanoma cell lines. J Invest Dermatol. 2002;119[3]:549-555. [CrossRef]
  • Yanagisawa M, Masaki T. Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol. 1989;38[12]:1877-1883. [CrossRef]
  • Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol. 1985;248[5 Pt 1]:C550-C556. [CrossRef]
  • Masaki T. The endothelin family: an overview. J Cardiovasc Pharmacol. 2000;35[4 Suppl 2]:S3-S5. [CrossRef]
  • Rozengurt E. Mitogenic signalling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007;213[3]:589-602. [CrossRef]
  • Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3[2]:110-116. [CrossRef]
  • Fischer OM, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans. 2003;31[Pt 6]:1203-1208. [CrossRef]
  • Gul N, Theuring F. Signal crosstalk promoted proliferative lesions in mouse mammary glands as a consequence of ET-1 overexpression. Experimed 2021; 11[1]: 1-10. [CrossRef]
  • Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer. 2005;92[12]:2148-2152. [CrossRef]
  • Morawietz H, Talanow R, Szibor M, Rueckschloss U, Schubert A, Bartling B, Darmer D, Holtz J. Regulation of the endothelin system by shear stress in human endothelial cells. J Physiol. 2000;525 Pt 3[Pt 3]:761-770. [CrossRef]
  • Henry PJ, Rigby PJ, Self GJ, Preuss JM, Goldie RG. Relationship between endothelin-1 binding site densities and constrictor activities in human and animal airway smooth muscle. Br J Pharmacol. 1990;100[4]:786-792. [CrossRef]
  • McKay KO, Black JL, Armour CL. The mechanism of action of endothelin in human lung. Br J Pharmacol. 1991;102[2]:422-428. [CrossRef]
  • Schinelli S. Pharmacology and physiopathology of the brain endothelin system: an overview. Curr Med Chem. 2006;13[6]:627-638. [CrossRef]
  • Harland SP, Kuc RE, Pickard JD, Davenport AP. Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-S411. [CrossRef]
  • Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacol Rev. 2016;68[2]:357-418. [CrossRef]
  • Maguire JJ, Davenport AP. Endothelin receptors and their antagonists. Semin Nephrol. 2015;35[2]:125-136. [CrossRef]
  • Egidy G, Juillerat-Jeanneret L, Jeannin JF, Korth P, Bosman FT, Pinet F. Modulation of human colon tumour-stromal interactions by the endothelin system. Am J Pathol. 2000;157[6]:1863-1874. [CrossRef]
  • Alanen K, Deng DX, Chakrabarti S. Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology. 2000;36[2]:161-167. [CrossRef]
  • Grimshaw MJ, Wilson JL, Balkwill FR. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumours. Eur J Immunol. 2002;32[9]:2393-2400. [CrossRef]
  • Mitrakas L, Gravas S, Karasavvidou F, Dimakopoulos G, Moutzouris G, Tzortzis V, Koukoulis G, Papandreou C, Melekos M. Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle- invasive bladder cancer Tumour Biol. 2015;36[6]:4699-4705. [CrossRef]
  • Eltze E, Wild PJ, Wülfing C, Zwarthoff EC, Burger M, Stoehr R, Korsching E, Hartmann A. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol. 2009;56[5]:837-845. [CrossRef]
  • Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumour endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest. 2011;121[1]:132-147. [CrossRef]
  • Maayah ZH, Takahara S, Alam AS, Ferdaoussi M, Sutendra G, El-Kadi A, Mackey JR, Pituskin E, Paterson DI, Dyck JRB. Breast cancer diagnosis is associated with relative left ventricular hypertrophy and elevated endothelin-1 signalling. BMC Cancer. 2020;20[1]:751. Published 2020 Aug 12. [CrossRef]
  • Wülfing P, Kersting C, Tio J, Fischer RJ, Wülfing C, Poremba C, Diallo R, Böcker W, Kiesel L. Endothelin-1, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res. 2004;10[7]:2393-2400. [CrossRef]
  • Zarnecki KG, Kristianto J, Charlson J, Wilson B, Blank RD, Shaker JL. Diffuse osteosclerosis as a presentation of recurrent breast cancer: role of endothelin 1. Osteoporos Int. 2019;30[8]:1699-1703. [CrossRef]
  • Restucci B, Martano M, Maiolino P. Expression of endothelin-1 and endothelin-1 receptor A in canine mammary tumours. Res Vet Sci. 2015;100:182-188. [CrossRef]
  • Liakou P, Tepetes K, Germenis A, Leventaki V, Atsaves V, Patsouris E, Roidis N, Hatzitheophilou K, Rassidakis GZ. Expression patterns of endothelin-1 and its receptors in colorectal cancer. J Surg Oncol. 2012;105[7]:643-649. [CrossRef]
  • Nie S, Zhou J, Bai F, Jiang B, Chen J, Zhou J. Role of endothelin A receptor in colon cancer metastasis: in vitro and in vivo evidence. Mol Carcinog. 2014;53 Suppl 1:E85-E91. [CrossRef]
  • Ali H, Dashwood M, Dawas K, Loizidou M, Savage F, Taylor I. Endothelin receptor expression in colorectal cancer. J Cardiovasc Pharmacol. 2000;36[5 Suppl 1]:S69-S71. [CrossRef]
  • Hoosein MM, Dashwood MR, Dawas K, Ali HM, Grant K, Savage F, Taylor I, Loizidou M. Altered endothelin receptor subtypes in colorectal cancer. Eur J Gastroenterol Hepatol. 2007;19[9]:775-782. [CrossRef]
  • Tao K, Wu C, Wu K, Li W, Han G, Shuai X, Wang G. Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer. Med Oncol. 2012;29[1]:107-112. [CrossRef]
  • Fukui R, Nishimori H, Hata F, Yasoshima T, Ohno K, Yanai Y, Kamiguchi K, Denno R, Sato N, Hirata K. Inhibitory effect of endothelin A receptor blockade on tumour growth and liver metastasis of a human gastric cancer cell line. Gastric Cancer. 2007;10[2]:123-128. [CrossRef]
  • Vasaikar S, Tsipras G, Landázuri N, Costa H, Wilhelmi V, Scicluna P, Cui HL, Mohammad AA, Davoudi B, Shang M, Ananthaseshan S, Strååt K, Stragliotto G, Rahbar A, Wong KT, Tegner J, Yaiw KC, Söderberg-Naucler C. Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?. BMC Cancer. 2018;18[1]:154. Published 2018 Feb 6. [CrossRef]
  • Egidy G, Eberl LP, Valdenaire O, Irmler M, Majdi R, Diserens AC, Fontana A, Janzer RC, Pinet F, Juillerat-Jeanneret L. The endothelin system in human glioblastoma. Lab Invest. 2000;80[11]:1681-1689. [CrossRef]
  • Anguelova E, Beuvon F, Leonard N, Chaverot N, Varlet P, Couraud PO, Daumas-Duport C, Cazaubon S. Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res. 2005;137[1-2]:77-88. [CrossRef]
  • Hinsley EE, Hunt S, Hunter KD, Whawell SA, Lambert DW. Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions. Int J Cancer. 2012;130[1]:40-47. [CrossRef] Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW, Lui WY. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma [HCC] in Taiwan. Oncol Rep. 2006;15[2]:507-511. [CrossRef]
  • Shi L, Zhou SS, Chen WB, Xu L. Functions of endothelin-1 in apoptosis and migration in hepatocellular carcinoma. Exp Ther Med. 2017;13[6]:3116-3122. [CrossRef]
  • Lu JW, Liao CY, Yang WY, Lin YM, Jin SLC, Wang HD, Yuh CH. Overexpression of endothelin 1 triggers hepatocarcinogenesis in zebrafish and promotes cell proliferation and migration through the AKT pathway. PLoS One. 2014;9[1]:e85318. Published 2014 Jan 8. [CrossRef]
  • Cong N, Li Z, Shao W, Li J, Yu S. Activation of ETA Receptor by Endothelin-1 Induces Hepatocellular Carcinoma Cell Migration and Invasion via ERK1/2 and AKT Signalling Pathways. J Membr Biol. 2016;249[1-2]:119-128. [CrossRef]
  • Knight LJ, Burrage J, Bujac SR, Haggerty C, Graham A, Gibson NJ, Ellison G, Growcott JW, Brooks AN, Hughes AM, Xinarianos G, Nikolaidis G, Field JK, Liloglou T. Epigenetic silencing of the endothelin-B receptor gene in non- small cell lung cancer. Int J Oncol. 2009;34[2]:465-471. [CrossRef]
  • Boldrini L, Gisfredi S, Ursino S, Faviana P, Lucchi M, Melfi F, Mussi A, Basolo F, Fontanini G. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer. 2005;41[18]:2828-2835. [CrossRef]
  • Mai HQ, Zeng ZY, Feng KT, Ye YL, Zhang CQ, Liang WJ, Guo X, Mo HY, Hong MH. Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer Sci. 2006;97[12]:1388-1395. [CrossRef]
  • Zhao Y, Liao Q, Zhu Y, Long H. Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin- induced apoptosis. Clin Orthop Relat Res. 2011;469[11]:3190-3199. [CrossRef]
  • Anggorowati N MD, PhD, Ghozali A MD, Widodo I MD, PhD, Sari DCR MD, PhD, Mansyur Romi M MD, MS, Arfian N MD, PhD. Upregulation of Endothelin-1/Endothelin A Receptor Expression Correlates with Heparanase Expression in Ovarian Carcinoma. Iran J Med Sci. 2018;43[3]:286-295. [CrossRef]
  • Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, Bagnato A. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 2005;65[24]:11649-11657. [CrossRef]
  • Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A. Endothelin A receptor/β-arrestin signalling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 2014;74[24]:7453-7464. [CrossRef]
  • Gupta S, Prajapati A, Gulati M, Gautam SK, Kumar S, Dalal V, Talmon GA, Rachagani S, Jain M. Irreversible and sustained upregulation of endothelin axis during oncogene-associated pancreatic inflammation and cancer. Neoplasia. 2020;22[2]:98-110. [CrossRef]
  • Cook N, Brais R, Qian W, Hak CC, Corrie PG. Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. J Clin Pathol. 2015;68[4]:309-313. [CrossRef]
  • Bhargava S, Stummeyer T, Hotz B, Hines OJ, Reber HA, Buhr HJ, Hotz HG. Selective inhibition of endothelin receptor A as an anti-angiogenic and anti-proliferative strategy for human pancreatic cancer. J Gastrointest Surg. 2005;9[5]:703-709. [CrossRef]
  • Godara G, Pecher S, Jukic DM, D'Antonio JM, Akhavan A, Nelson JB, Pflug BR. Distinct patterns of endothelin axis expression in primary prostate cancer. Urology. 2007;70[1]:209-215. [CrossRef]
  • Douglas ML, Richardson MM, Nicol DL. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer. 2004;100[10]:2118-2124. [CrossRef]
  • Herrmann E, Eltze E, Bierer S, Bogemann M, Brinkmann OA, Balnowair H, Hertle L, Wulfing C. Expression of the Endothelin-axis in the different histologic subtypes of renal cell carcinoma: a tissue microarray analysis. Oncol Rep. 2007;17[2]:275-280. [CrossRef]
  • Wuttig D, Zastrow S, Füssel S, Toma MI, Meinhardt M, Kalman K, Junker K, Sanjmyatav J, Boll K, Hackermüller J, Rolle A, Grimm MO, Wirth MP. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumours and metastases. Int J Cancer. 2012;131[5]:E693-E704. [CrossRef]
  • Ishimoto S, Wada K, Tanaka N, Yamanishi T, Ishihama K, Aikawa T, Okura M, Nakajima A, Kogo M, Kamisaki Y. Role of endothelin receptor signalling in squamous cell carcinoma. Int J Oncol. 2012;40[4]:1011-1019. [CrossRef]
  • Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumour progression marker in malignant melanoma. Virchows Arch. 2001;438[5]:485-491. [CrossRef]
  • Irani S, Salajegheh A, Gopalan V, Smith RA, Lam AK. Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristics. Ann Diagn Pathol. 2014;18[2]:43-48. [CrossRef]
  • Aydin AF, Vural P, Doğru-Abbasoğlu S, Çil E. The endothelin 1 and endothelin receptor A gene polymorphisms increase the risk of developing papillary thyroid cancer. Mol Biol Rep. 2019;46[1]:199-205. [CrossRef]
  • Smith SL, Damato BE, Scholes AG, Nunn J, Field JK, Heighway J. Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. Br J Cancer. 2002;87[11]:1308-1313. [CrossRef]
  • Höckel M, Vaupel P. Tumour hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93[4]:266-276. [CrossRef]
  • Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK.. Regulation of transport pathways in tumour vessels: role of tumour type and microenvironment. Proc Natl Acad Sci U S A. 1998;95[8]:4607-4612. [CrossRef]
  • Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumours: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A. 2000;97[26]:14608-14613. [CrossRef]
  • Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest. 1991;88[3]:1054-1057. [CrossRef]
  • Bagnato A, Spinella F, Rosanò L. Emerging role of the endothelin axis in ovarian tumour progression. Endocr Relat Cancer. 2005;12[4]:761-772. [CrossRef]
  • Zhang Q, Zhang ZF, Rao JY, Sato JD, Brown J, Messadi DV, Le AD. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer. 2004;111[6]:849-857. [CrossRef]
  • Van der Schaft DW, Hillen F, Pauwels P, Kirschmann DA, Castermans K, Egbrink MGAO, Tran MGB, Sciot R, Hauben E, Hogendoorn PCW, Delattre O, Maxwell PH, Hendrix MJC, Griffioen AW. Tumour cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005;65[24]:11520-11528. [CrossRef]
  • Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA. "Vasocrine" formation of tumour cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res. 2003;63[11]:2812-2819. [CrossRef]
  • Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer [published correction appears in Eur J Clin Invest. 2009 Jul;39[7]:630]. Eur J Clin Invest. 2009;39 Suppl 2:74-77. [CrossRef]
  • Kojima K, Nihei Z. Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol. 1995;4[6]:309-315. [CrossRef]
  • Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer. 2005;92[12]:2148-2152. [CrossRef]
  • Barton M, Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019;74[6]:1232-1265. [CrossRef]
  • Wülfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Rody A, Greb RR, Böcker W, Kiesel L. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res. 2003;9[11]:4125-4131. [CrossRef]
  • Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol. 2001;165[3]:1033-1036. [CrossRef]
  • Bagnato A, Rosanò L. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs. 2007;185[1-3]:85-94. [CrossRef]
  • Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2[6]:442-454. [CrossRef]
  • Bagnato A, Rosanò L. The endothelin axis in cancer. Int J Biochem Cell Biol. 2008;40[8]:1443-1451. [CrossRef]
  • Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007;7[6]:415-428. [CrossRef]
  • Rosanò L, Spinella F, Bagnato A. The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. Am J Physiol Regul Integr Comp Physiol. 2010;299[2]:R395-R404. [CrossRef]
  • Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17[8]:2350-2360. [CrossRef]
  • Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein- coupled receptors. Nature. 1996;379[6565]:557-560. [CrossRef]
  • Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signalling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 2006;66[24]:11831-11839. . [CrossRef]
  • Ye P, Wang Y, Li R, Chen W, Wan L, Cai P. The HER family as therapeutic targets in colorectal cancer. Crit Rev Oncol Hematol. 2022;174:103681. [CrossRef]
  • Xie Z, Zhong C, Shen J, Jia Y, Duan S. LINC00963: A potential cancer diagnostic and therapeutic target. Biomed Pharmacother. 2022;150:113019. [CrossRef]
  • Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signalling Mechanisms, Drugs, and Acquired Resistance. Cancers [Basel]. 2021;13[11]:2748. Published 2021 Jun 1. [CrossRef]
  • Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor [EGFR] inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem. 2020;99:103811. [CrossRef]
  • Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res. 1995;1[9]:1059-1066. [CrossRef]
  • Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published correction appears in Cell 1998 Jul 24;94[2]:273]. Cell. 1998;93[5]:705-716. [CrossRef]
  • Cianfrocca R, Rosanò L, Tocci P, Sestito R, Caprara V, Di Castro V, Maria RD, Bagnato A. Blocking endothelin-1- receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death Differ. 2017;24[10]:1811-1820. [CrossRef]
  • Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosanò L. β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells. Life Sci. 2014;118[2]:179-184. [CrossRef]
  • McKenzie GA, Hinsley EE, Hunter K, Lambert DW. The endothelin axis in head and neck cancer: a promising therapeutic opportunity?. J Oral Pathol Med. 2014;43[6]:395-404. [CrossRef]
  • Nalivaeva NN, Belyaev ND, Kerridge C, Turner AJ. Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front Aging Neurosci. 2014;6:235. Published 2014 Sep 17. [CrossRef]
  • Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49[D1]:D1388-D1395. [CrossRef]
  • Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004;43[15]:1089-1115. [CrossRef]
  • Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo- controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer. 2010;9:69. Published 2010 Mar 30. [CrossRef]
  • Buckley MS, Wicks LM, Staib RL, Kirejczyk AK, Varker AS, Gibson JJ, Feldman JP. Pharmacokinetic evaluation of ambrisentan [published correction appears in Expert Opin Drug Metab Toxicol. 2011 May;7[5]:673]. Expert Opin Drug Metab Toxicol. 2011;7[3]:371-380.
  • Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp Pharmacol. 2013;218:199-227. [CrossRef]
  • Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ.. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics [published correction appears in J Clin Oncol. 2003 Jun 15;21[12]:2449]. J Clin Oncol. 2002;20[8]:2171-2180. [CrossRef]
  • Clarkson-Jones JA, Kenyon AS, Kemp J, Lenz EM, Oliver SD, Swaisland H. Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan [ZD4054] in healthy volunteers. Xenobiotica. 2012;42[4]:363- 371. [CrossRef]
  • Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T. Pharmacokinetics and tolerability of zibotentan [ZD4054] in subjects with hepatic or renal impairment: two open-label comparative studies. BMC Clin Pharmacol. 2011;11:3. Published 2011 Mar 17. [CrossRef]
  • Chavez E, Rodriguez J, Drexler Y, Fornoni A. Novel Therapies for Alport Syndrome. Front Med [Lausanne]. 2022;9:848389. Published 2022 Apr 25. [CrossRef]
  • Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022;2[2]:CD003233. Published 2022 Feb 28. [CrossRef]
  • Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007;25[8]:785-794.. [CrossRef]
  • Sidharta PN, Melchior M, Kankam MK, Dingemanse J. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects. Drug Des Devel Ther. 2019;13:949-964. Published 2019 Mar 22. [CrossRef]
  • Angeli F, Verdecchia P, Reboldi G. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. Cardiol Ther. 2021;10[2]:397-406. [CrossRef]
  • Benedict NJ. Sitaxsentan in the management of pulmonary arterial hypertension. Am J Health Syst Pharm. 2007;64[4]:363-368. [CrossRef]
  • Enseleit F, Lüscher TF, Ruschitzka F. Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. Ther Adv Cardiovasc Dis. 2010;4[4]:231-240. [CrossRef]
  • Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21[3]:527-535. [CrossRef]
  • Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther. 2006;110[3]:386-414. [CrossRef]
  • van Giersbergen PL, Dingemanse J. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol. 2007;63[2]:151-158. [CrossRef]
  • uif PE, Dingemanse J, Ufer M. Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm. Front Pharmacol. 2021;11:628956. Published 2021 Feb 4. [CrossRef]
  • Ihara M, Fukuroda T, Saeki T, Nishikibe M, Kojiri K, Suda H, Yano M. An endothelin receptor [ETA] antagonist isolated from Streptomyces misakiensis. Biochem Biophys Res Commun. 1991;178[1]:132-137. [CrossRef]
  • Okada M, Nishikibe M. BQ-788, a selective endothelin ET[B] receptor antagonist. Cardiovasc Drug Rev. 2002;20[1]:53-66. [CrossRef]
  • Berger Y, Bernasconi CC, Juillerat-Jeanneret L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med [Maywood]. 2006;231[6]:1111-1119. [CrossRef]
  • Dang D, Ye Y, Aouizerat BE, Patel YK, Viet DT, Chan KC, Ono K, Doan C, Figueroa JD, Yu G, Viet CT. Targeting the endothelin axis as a therapeutic strategy for oral cancer metastasis and pain. Sci Rep. 2020;10[1]:20832. Published 2020 Nov 30. [CrossRef]
  • Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS, He J, Langley RR, Lehembre F, Regenass U, Fidler IJ. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro Oncol. 2016;18[4]:486-496. [CrossRef]
  • Kappes L, Amer RL, Sommerlatte S, Bashir G, Plattfaut C, Gieseler F, Gemoll T, Busch H, Altahrawi A, Al-Sbiei A, Haneefa SM, Arafat K, Schimke LF, El Khawanky N, Forster KS, Heidecke H, Kerstein-Staehle A, Marschner G, Pitann S, Ochs HD, Mueller A, Attoub S, Fernandez-Cabezudo MJ, Riemekasten G, Al-Ramadi BK, Marques OC. Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. Sci Rep. 2020;10[1]:15931. Published 2020 Sep 28. [CrossRef]
  • Chouaid C, Nathan F, Pemberton K, Morris T. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan [ZD4054] in combination with pemetrexed in patients with advanced non- small cell lung cancer. Cancer Chemother Pharmacol. 2011;67[5]:1203-1208. [CrossRef]
  • Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan [ZD4054] in patients with non- metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2013;16[2]:187-192. [CrossRef]
  • Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage [CONSCIOUS-1]: randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39[11]:3015-3021. [CrossRef]
  • Chaumais MC, Guignabert C, Savale L, Jaïs X, Boucly A, Montani D, Simonneau G, Humbert M, Sitbon O. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2015;15[1]:13-26. [CrossRef]
  • Galiè N, Hoeper MM, Gibbs JS, Simonneau G. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J. 2011;37[2]:475-476. [CrossRef]
There are 122 citations in total.

Details

Primary Language English
Subjects Basic Pharmacology
Journal Section Reviews
Authors

Nadir Gül

Publication Date June 27, 2025
Published in Issue Year 2023 Volume: 27 Issue: 2

Cite

APA Gül, N. (2025). The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies. Journal of Research in Pharmacy, 27(2), 22-33.
AMA Gül N. The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies. J. Res. Pharm. June 2025;27(2):22-33.
Chicago Gül, Nadir. “The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies”. Journal of Research in Pharmacy 27, no. 2 (June 2025): 22-33.
EndNote Gül N (June 1, 2025) The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies. Journal of Research in Pharmacy 27 2 22–33.
IEEE N. Gül, “The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies”, J. Res. Pharm., vol. 27, no. 2, pp. 22–33, 2025.
ISNAD Gül, Nadir. “The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies”. Journal of Research in Pharmacy 27/2 (June 2025), 22-33.
JAMA Gül N. The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies. J. Res. Pharm. 2025;27:22–33.
MLA Gül, Nadir. “The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies”. Journal of Research in Pharmacy, vol. 27, no. 2, 2025, pp. 22-33.
Vancouver Gül N. The Role of Endothelin Axis in Cancer Treatment and Its Position in Therapeutic Strategies. J. Res. Pharm. 2025;27(2):22-33.